Navigation Links
First Patient Treated in U.S. Clinical Study of Cohera Medical's TissuGlu® Surgical Adhesive
Date:5/1/2012

PITTSBURGH, May 1, 2012 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, today announced the treatment of the first patient in a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu® Surgical Adhesive in the United States.  Initiation of the study marks a significant milestone in the Company's progression of the lead product toward commercialization in the United States.

The study will investigate the effectiveness of TissuGlu on the reduction of wound drainage and post-surgical complications in abdominoplasty surgeries in 150 patients at six sites in the U.S. TissuGlu is a resorbable, high-strength surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that helps eliminate or reduce fluid accumulation and the need for post surgical drains. Enrollment in the study is expected to proceed quickly and upon favorable conclusion will allow the company to complete a PMA application for TissuGlu with the FDA.

"We are excited to have treated the first patient in the TissuGlu study," said Joseph P. Hunstad MD, FACS, of the The Hunstad-Kortesis Center, Charlotte, N.C.  "We look forward to enrolling more patients and believe that these procedures represent a key step forward in helping patients recover faster and more comfortably following large flap procedures."

"Initiation of the US clinical trial is a major milestone for Cohera," said Patrick Daly, President and Chief Executive Officer of Cohera Medical.  "We are honored to be working with such a distinguished group of surgeons who share our vision for excellent clinical outcomes.  We look forward to working with FDA to bring this breakthrough technology to patients and clinicians here in the United States."

Cohera Medical recently received

SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
2. Hospira Reports First-Quarter 2012 Results
3. Rigel Announces First Quarter 2012 Financial Results
4. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
5. Luminex Corporation Reports First Quarter 2012 Results
6. Halozyme to Host First Quarter 2012 Financial Results Conference Call
7. Anthera Announces First Quarter 2012 Financial Report and Conference Call
8. Chindex International, Inc. to Report First Quarter 2012 Financial Results
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Deutschland, 31. Juli 2014  invendo medical ... („robotischen") Koloskopie-Systems für den Einmalgebrauch, verkündete heute, ... weltweit anerkannter Manager im Bereich Medizintechnik, als ... stößt. Logo - ... hochangesehener globaler Visionär der Medizintechnikbranche. Er war ...
(Date:7/31/2014)... July 31, 2014 Nutrastar International Inc. (OTCQB: ... supplier of premium branded consumer products, including commercially cultivated ... foods, today announced the signing of its first distributor ... expansion to Hubei Province ... Central China . The contract ...
(Date:7/31/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... $70.1 million for the second quarter ended June 30, ... revenue for the same period of 2013. ... Assist Systems were sold globally compared to 523 units ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12
... Who Take DHA Have Healthier Pregnancies, Fewer Premature Births, ... nutritional,experts from a European Union (EU) committee now recommend ... basis with a large amount,of DHA, an essential omega-3 ... growing array of health benefits, nutritional,supplementation of DHA is ...
... Agent Administered in First-In-Human Study to Cancer Patients, ... Pharmaceuticals, Inc.,today announced that its first-in-humans Phase 1 ... is designed to evaluate the safety,pharmacokinetic and pharmacodynamic ... tumors. Study sites include TGen Clinical Research at,Scottsdale ...
Cached Medicine Technology:European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day 2Prolexys Pharmaceuticals Initiates Phase 1 Study 2
(Date:7/31/2014)... Ottawa, Ontario (PRWEB) July 31, 2014 ... s deliver fitness to your home, which now includes ... certified personal trainers have been delivering fitness to clients ... Ottawa. Fitness on the Go is a Canadian owned ... to helping communities achieve a healthier and fitter lifestyle. ...
(Date:7/31/2014)... July 31, 2014 In a front-page ... pharmaceutical giant, Johnson & Johnson, is withdrawing its laparoscopic ... spread undetected cancer. This important story has also ... Today (7/31), the AP (7/30), the Pittsburgh Business Times ... is used during uterine procedures to, “slice up common ...
(Date:7/31/2014)... ARBORA new bill introduced in Congress with bipartisan support ... University of Michigan research, which could improve the health ... spend on the medicines and tests they need most. ... Diane Black and Earl Blumenauer, grew out of a ... the U-M,s Institute for Healthcare Policy and Innovation. It ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go Grows to Ottawa 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3
... suffering encountered by men who underwent surgery for hernia was ... delayed surgeries and felt almost no symptoms, after a period ... were also reported to be the same. Most men who ... either minimally symptomatic or asymptomatic. They usually wait until the ...
... doctors and pharmacists in the U.S. are not aware that ... drugs of the same brand name or a similar sounding ... U.S. Food and Drug Administration (FDA) //said medication name mix-ups ... buying and using the wrong medicine. ...
... 12 babies born in New South Wales are due to ... obstetricians working at the private hospitals. ,About 25% ... drugs to initiate labour. // ,The doctors when asked ... as they want that particular doctor to handle their pregnancy. ...
... upset and has sent a letter to the acting head of ... letter he had asked the FDA to provide a full account ... reveled that the tainted tissues were used for the patients in ... into the matter about the case of the Brooklyn funeral home ...
... incidence of Polio in Bihar state has led to much ... state stands unparalled with respect to the number of polio ... for provision of polio drops to children less than 5 ... recently. ,National Cadet Corps volunteers embarked on ...
... The Royal National Institute of Deaf People with collaboration with ... aims at checking the hearing capacity of 28 million people ... is estimated that more than 4 million people in United ... to be treated which requires early diagnosis. ,The ...
Cached Medicine News:Health News:Drug Name Confusion Makes Imports Dangerous: FDA 2Health News:New trend of birth induction is on the rise 2Health News:Bihar Health Officials Worried As Polio Cases Soar 2
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, offers ... space saving, 2-level design. Up to 27 reservoirs ... give you the flexibility to tailor your staining ... Two start stations allow for continuous loading; The ...
Medicine Products: